Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
The author:Go Top Biotech    Released in:2021年05月07日
摘要:A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone.

Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used in the treatment of obesity because it induces weight loss and maintains low-calorie diet–induced weight loss for at least 1 year, primarily by means of appetite inhibition.Whether exercise, medication, or a combination strategy constitutes the more effective approach for maintaining healthy weight loss remains an open question. We investigated the efficacy of 1-year treatment with a moderate-to-vigorous–intensity exercise program, liraglutide at a dose of 3.0 mg per day, or the combination of exercise plus liraglutide, as compared with placebo, for healthy weight loss maintenance after weight loss induced by a low-calorie diet.


The trial was conducted from August 2016 through November 2019. A total of 215 participants initiated the low-calorie diet, of whom 195 had a weight loss of at least 5% of their baseline body weight; these 195 participants underwent randomization. A total of 166 participants (85%), including 40 of 48 (83%) in the exercise group, 41 of 49 (84%) in the liraglutide group, 45 of 49 (92%) in the combination group, and 40 of 49 (82%) in the placebo group, attended the visit for the assessment of the primary end point at week 52 (Figure 1A and Table S13). The reasons that participants missed the assessment visit are shown in Figure S1. The demographic characteristics of the participants at randomization were similar across the trial groups (Table S3).


Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

The characteristics of the participants before and after the low-calorie diet are shown in Table 1. During the 8-week low-calorie diet, the participants’ body weight decreased by a mean of 13.1 kg (95% confidence interval [CI], 12.4 to 13.7), which was equivalent to a mean reduction in body weight of 12%. This decrease was accompanied by decreases in the body-fat percentage, waist circumference, waist-to-hip ratio, glycated hemoglobin level, blood pressure, lipid levels, resting heart rate, and HOMA-IR. The Matsuda index, cardiorespiratory fitness, general health perception, physical functioning, and emotional well-being increased (Table S2).

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined


In this randomized, head-to-head, placebo-controlled trial, we investigated exercise, liraglutide, and both treatments combined for healthy weight loss maintenance. All active-treatment groups decreased body weight and body-fat percentage after 1 year, as compared with the increases observed in the placebo group. The combined strategy reduced the body weight and body-fat percentage approximately twice as much as the single-treatment strategies did and was associated with additional health benefits, such as improvements in the glycated hemoglobin level, insulin sensitivity, cardiorespiratory fitness, physical functioning, and emotional well-being.


References:

https://www.nejm.org/doi/full/10.1056/NEJMoa2028198


Hangzhou Go Top Peptide Biotech is a technology-based peptide company and National High-tech Enterprise located in Hangzhou, China. And has an experienced scientific research team that can provide customers with high-quality products and professional services.Main service include Custom peptide synthesis, Peptide CRO/CDMO,Non-GMP and GMP peptide, Cosmetic peptide. For any requests of Peptide for research purpose,welcome to contact us.  www.gtpeptide.com,  sales3@gotopbio.com.

Tel: +86-571-88211951 , 88211921. Fax:+86-571-88211907
Email: sales@gotopbio.com, Sales1@gotopbio.com
Add: Room 501, Building 1, No. 600, Yinhai Street, Qiantang New District, Hangzhou 310018, Zhejiang, P.R.China. 浙ICP备18017542号-1